Oncology Drug Combos Are Held Back By IP Issues, Not FDA, Pazdur Tells ASCO
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of oncology drug combination products is more often held back by intellectual property issues than by FDA regulatory requirements, Oncologic Drug Products Division Director Richard Pazdur said during the American Society of Clinical Oncology meeting in New Orleans June 5